FRANKFURT (Reuters) -A next-generation cancer immunotherapy by BioNTech and partner Bristol Myers Squibb led to encouraging tumour shrinkage in a mid-stage trial on small cell lung cancer that has started spreading, the German biotech firm said on Monday.

A Phase II trial showed that 76.3% of the 38 participants on the drug BNT327, also know as pumitamig, who qualified for an interim analysis saw their tumours shrink, BioNTech said in a statement.

The drug candidate, which was used in combination with chemotherapy, demonstrated a manageable safety profile with no new safety concerns and a low rate of people dropping out due to side effects, it added.

The drug is already being tested in a Phase III lung cancer trial.

Bristol Myers in June agreed to pay up to $11.1 billion to collaborate

See Full Page